Ornithine transcarbamylase deficiency …

Neurogenetic Disorders

Updated 02.27.2024
Released 11.28.1994
Expires For CME 02.27.2027

Ornithine transcarbamylase deficiency

Authors: Roland Posset MD, Matthias Zielonka MD, Georg F Hoffmann MD

See Contributor Disclosures

Editor: Barry Wolf MD PhD

Ornithine transcarbamylase deficiency

In This Article

Quick Link

Introduction

Overview

Ornithine transcarbamylase deficiency (OTCD) is the most common inherited urea cycle disorder and the only one to be transmitted as an X-linked trait. It causes hyperammonemia, intellectual disability, (severe) developmental disabilities, and fluctuating neurologic and psychiatric symptoms, and it may be fatal unless treated with liver transplantation. Complete enzyme deficiency in affected hemizygous males almost invariably results in hyperammonemic coma within the first days or weeks of life (28 or fewer days; neonatal or early onset), whereas partial deficiency in males or manifesting heterozygous females can result in hyperammonemia at any age (more than 28 days; late onset). Biochemical markers include elevated plasma glutamine and reduced or absent L-arginine and L-citrulline concentrations on amino acid analysis together with elevated concentrations of urinary orotic acid. Diagnosis is established by identifying the mutation or by enzyme analysis of liver tissue or intestinal mucosa. Treatment consists of a protein-restricted diet, ammonia scavenger drugs, and L-citrulline or L-arginine substitution. Liver transplantation cures recurrent hyperammonemic episodes, but will not restore neurologic sequelae.

Currently, international networks for rare metabolic diseases (UCDC, E-IMD, JUCDC) aim to more completely describe the initial and evolving clinical phenotype of urea cycle disorders (UCD) such as ornithine transcarbamylase deficiency. Furthermore, they want to determine if the natural disease course can be favorably modulated by diagnostic and therapeutic interventions. These networks collect systematic data to improve clinical knowledge, develop guidelines, and provide patients and professionals with reliable data on disease manifestation and complications, as well as long-term outcomes of urea cycle disorders. These networks include the Urea Cycle Disorders Consortium (UCDC), established in 2006, the European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD), established in 2011, and the Japanese Urea Cycle Disorders Consortium (JUCDC), established in 2012 (103).

Key points

	• Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder as well as the only X-linked urea cycle disorder.
	• Deleterious mutations cause severe male neonatal-onset type disease and mild to severe disease in females (depending on lyonization). Less severe mutations with partial enzyme deficiency cause mild to moderate late-onset type disease in males and females.
	• Clinical presentation of heterozygous female OTC carriers is highly variable, even within the same family because of different X-inactivation.
	• Female carriers are at special risk of severe metabolic decompensation after birth.
	• Neurologic outcome depends primarily on noninterventional parameters, eg, intrinsic disease severity (reflected by onset type and initial peak plasma ammonium concentration during first metabolic decompensation). The impact of interventional parameters on clinical outcomes, eg, diagnostic and therapeutic interventions, is subject to future studies.

Historical note and terminology

Ornithine transcarbamylase deficiency (OTCD) was first reported in 1962 in two girls, aged 20 months and 6 years, who were found to have hyperammonemia associated with episodic vomiting, delirium, stupor, failure to thrive, and mental retardation (92). The mothers of the patients were sisters, and both showed evidence of a similar metabolic disorder. Both girls died before the age of 8 years. Several years later, this disorder was also identified in males (99), and the delayed recognition was attributable to the almost total lack of enzyme activity and rare survival of affected males beyond the newborn period at that time. The reason for this difference between males and females was subsequently determined in the X-linked trait (91).

Clinical manifestations

Presentation and course

The classic presentation of ornithine transcarbamylase deficiency in hemizygous males is as catastrophic illness in the first week of life (neonatal/early onset). This accounts for approximately one third of all cases (102; 76); however, neonatal-onset male patients might be underrepresented in statistical analyses due to early and undiagnosed death. Typically, the affected baby is born after an uncomplicated full-term pregnancy, labor, and delivery with normal Apgar scores. Compared to distal urea cycle disorders (argininosuccinate synthetase 1 deficiency and argininosuccinate lyase deficiency), subjects with carbamoyl phosphate synthetase 1 deficiency (CPS1D) and ornithine transcarbamylase deficiency present earlier, usually within 24 to 72 hours after birth and with a higher initial peak-blood ammonia concentration (02).

Ammonia detoxification

Ammonia is detoxified through its conversion to urea by the enzymes in the small boxes, whose abbreviations are spelled out below. OTC catalyzes the synthesis of citrulline from carbamoyl phosphate and ornithine. Deficiency of OTC...

Symptoms remind of a neonatal sepsis-like picture with hyperventilation, respiratory distress, and temperature instability. Respiratory alkalosis is often seen. Poor sucking, vomiting, and muscular hypotonia may be observed. Symptoms rapidly progress from somnolence and lethargy to coma (37). Neurologic findings may include increased deep tendon reflexes and papilledema. Convulsions may already be late complications and follow alterations in consciousness. Results from the Urea Cycle Disorders Consortium (UCDC) reported neuroimaging and neurocognitive findings of more than 600 patients with urea cycle disorder, including patients suffering from male and female ornithine transcarbamylase disorder (n = 320). Acute hyperammonemic episodes demonstrate a diffuse or focal pattern of cerebral MRI changes and brain edema (21; 35; 96). However, the impact of (acute) cerebral changes on clinical long-term outcomes; thus, the predictive value of diagnostic imaging, is yet to be determined and subject to future analyses (82; 96). An analysis of MRIs during a stable metabolic condition of individuals with ornithine transcarbamylase deficiency showed structural, biochemical, and functional changes in the brain between symptomatic subjects and normal controls (33).

In symptomatic heterozygous females and in males with partial ornithine transcarbamylase deficiency, symptoms rarely occur in the newborn period. In this group of patients, there is a wide spectrum of presentations after the newborn period even within the same family, with some individuals developing hyperammonemic episodes in infancy or early childhood, others in later childhood, and still others not until adulthood, with pregnancy and diet changes constituting some of the precipitating causes (23; 11). Symptoms may be delayed in onset by avoidance of trigger factors, eg, dietary self-restriction (self-avoidance of meats, fish, eggs, milk, and other high-protein foods). The occurrence of some chronic hyperammonemic symptoms appears to be age-specific. In infants, hepatodigestive (eg, episodes of vomiting, feeding problems, hepatopathy) and recurrent neurologic symptoms (eg, lethargy, irritability, psychomotor/mental retardation, movement disorder, convulsions, and coma) are common. It has been suggested that patients with late-onset urea cycle disorder most often present with progressive intellectual disability, movement disorders, and epilepsy (55). In older children and adults, behavioral abnormalities (eg, biting, self-injury, nocturnal restlessness, hyperactivity) and psychiatric signs (eg, confusion, irritability, agitation, headache, and aggression) can be found (55). Especially in adults, symptoms may mimic specific psychiatric or neurologic disorders (04; 22). In such patients, chronic hyperammonemic symptoms normally precede acute metabolic decompensation and are often unfortunately only identified retrospectively. However, urea cycle disorders in adults still remain a life-threatening condition (107). Asymptomatic female ornithine transcarbamylase deficiency individuals might present clinically with neurologic or psychiatric signs during the postpartum period (29; 59; 37). A study found that maternal ornithine transcarbamylase deficiency is associated with high maternal and neonatal morbidity and mortality when diagnosis is made during the pregnancy compared to when a diagnosis of female ornithine transcarbamylase deficiency is known prior to pregnancy, which shows why gynecologists or general practitioners should be aware of the above-described clinical presentation of chronic hyperammonemia or acute decompensation during pregnancy (108). Stroke-like episodes have also been described (22; 46). Some patients may present with acute liver failure (106). Analysis of a Swiss patient cohort showed that hepatic complications of urea cycle disorders, especially in individuals suffering from ornithine transcarbamylase deficiency, may be underrecognized (58). Liver involvement was a reported complication found in 100% of male and 40% of symptomatic female patients with ornithine transcarbamylase deficiency at least once during their life. However, bleeding complications and vitamin K dependence are rare.

In some urea cycle disorders, adults performed less well than younger patients in neurocognition; however, it remains unclear whether this is due to decline throughout life or improvements in diagnostics and treatment. Patients suffering from ornithine transcarbamylase deficiency tended not to have declined scores over time (117). Another study suggested that intellectual impairment is global rather than domain-specific and is associated with disease onset, gender, maximum ammonia concentration, and number of hyperammonemic events (15).

Triggers for acute metabolic manifestation of late-onset ornithine transcarbamylase deficiency include switching from low-protein breast milk to high-protein formula or cow milk, fever, infections, vomiting, gastrointestinal bleeding, decreased energy or protein intake, and surgery. Importantly, also drugs, especially valproate, steroids, haloperidol, and L-asparaginase/pegaspargase (79), and the postpartum period (due to catabolism and the involution of the uterus) are important trigger factors for late-onset hyperammonemia (29; 37; 59). There is some evidence that carnitine may protect against valproate-induced hyperammonemia in urea cycle disorders (31).

Prognosis and complications

Both in males and females, mortality is still an important topic in neonatal-/early-onset ornithine transcarbamylase deficiency. Mortality rates of patients with early-onset ornithine transcarbamylase deficiency who had been diagnosed between the mid-70s and mid-90s of the past century were very poor, with more than 85% of patients dying during the initial episode (114; 77). According to a study from Japan, nowadays survival rates have improved significantly for both early and late-onset ornithine transcarbamylase deficiency, with survival rates of approximately 85% for male neonatal onset ornithine transcarbamylase deficiency and more than 95% for late-onset ornithine transcarbamylase deficiency (49). However, a review and meta-analysis of observational studies spanning a period of more than 35 years demonstrated that early-onset patients, among those with ornithine transcarbamylase deficiency, still have a high risk of early death (16). Survival of males with ornithine transcarbamylase deficiency was only 15% by the end of the first year in that study. Survival of female patients with ornithine transcarbamylase deficiency is unknown because of the lack of sufficient data. Surprisingly, no significant improvement in survival for urea cycle disorders was observed over a period of more than 30 years (16), which is in contrast to the higher survival rate reported in the study from Japan (49).

Morbidity in urea cycle disorders remains high in survivors of neonatal hyperammonemic coma. Frequent comorbidities in urea cycle disorders are associated with the most vulnerable organ (ie, the brain) (56) and lead to intellectual disability, cerebral palsy, seizure disorder, and visual deficits (69; 15). A study of long-term survivors demonstrated that approximately only half of the patients had IQ scores greater than 85, and most of these patients had late-onset disease manifestation or were diagnosed and treated prospectively, ie, before onset of clinical symptoms conceding poor outcome for early-onset disease manifestation (114). Other data, however, demonstrate that neurocognitive outcome is independent of the age at which the first symptoms are noted or the age at diagnosis but does essentially depend on the initial peak-blood ammonia concentration (07; 28). At the first hyperammonemic attack, peak-blood ammonia concentrations of less than 180 µmol/L are associated with good outcomes, and peak-blood ammonia concentrations of more than 360 µmol/L are markers of poor prognoses. Variable outcome is observed when peak-blood ammonia concentration is between 180 and 360 µmol/L (114; 49). The intrinsic disease severity, which is reflected by the onset type and initial peak-blood ammonia concentration, affects the neurologic outcome of individuals with urea cycle disorders (86).

Importantly, current clinical knowledge suggests that cognitive outcome at the last regular visit differs between patients with proximal (ie, carbamoyl-phosphate synthetase 1 deficiency, ornithine transcarbamylase deficiency) and distal defects (ie, argininosuccinate synthetase deficiency, argininosuccinate lyase deficiency); the latter group being more compromised despite lower initial peak blood ammonium concentrations (89). Furthermore, a study demonstrated no difference in movement disorders (ie, dystonia, spasticity, chorea, ataxia) with regard to proximal versus distal urea cycle disorders; however, compared to patients with early-onset disease manifestations, patients with late-onset urea cycle disorders developed movement disorders and motor abnormalities less often (56; 86). A detailed overview of organ-specific disease manifestations and complications in patients suffering from urea cycle disorders (eg, OTCD) has been provided by Kölker and colleagues (56).

In a study of 19 women heterozygous for ornithine transcarbamylase deficiency Gyato and colleagues found normal overall IQ scores, but significant deficiencies in nonverbal intelligence, visual memory, attention or executive skills, and math, suggesting selective vulnerability of white matter and better preservation of gray matter (36). However, this notion is challenged by a study suggesting that impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain-specific (15). Individuals with urea cycle disorders suffer from increased frequencies of mental disability and behavioral/emotional problems; however, they experience a normal health-related quality of life (45).

Clinical vignette

Patient 1: Late-onset female OTCD. The following is a summary of a case of a previously reported 3-year-old girl (106). The child was born after an uncomplicated pregnancy and delivery to nonconsanguineous parents, which was succeeded by an uneventful newborn period and early development. The girl had developed aggressive behavior starting in late infancy and intermittently severe sleeping difficulties from 3 years of age. Eight weeks before admission, the child started to vomit and became lethargic without being able to eat or drink intermittently. She recovered from that period, but 1 week before admission, she started to deteriorate and blood tests showed elevated liver enzymes (aspartate aminotransferase (AST) 5756 U/L, alanine aminotransferase (ALT) 4397 U/L). Three days later after a protein-rich meal she developed loss of appetite and drowsiness leading to admission. The initial work-up revealed hyperammonemia of 161 µmol/L. Emergency treatment was initiated and aminotransferases slowly recovered. Elevated orotic acid in urine (1323 mmol/mol creatinine; n < 4.41) and increased plasma glutamine were detected. Emergency treatment was intensified and adapted to ornithine transcarbamylase deficiency-specific requirements. At this point, AST and ALT were below 1000 U/L, and INR and lactate dehydrogenase were elevated. Factor V activity was reduced, whereas fibrinogen was normal. Administration of vitamin K did not improve INR. INR further increased necessitating the substitution with fresh-frozen plasma. The following day, parameters did not improve, and the patient developed hepatic encephalopathy and coma. There were no signs of brain edema on cranial CT, but a slight reduction of brain volume. Differential diagnoses included hepatotropic viruses, alpha-1 antitrypsin deficiency, autoimmune hepatitis, and cholangitis, which could all be excluded. Despite biochemical improvement during emergency treatment (decrease in urinary excretion of orotic acid, decrease in ammonia concentrations), the girl remained encephalopathic, and the hepatic function did not recover. Liver transplantation was considered and the girl was registered with Eurotransplant for high urgency liver transplantation and received a suitable donor organ 19 hours thereafter. Suspected ornithine transcarbamylase deficiency was confirmed by enzymatic analysis of the explanted liver showing a residual ornithine transcarbamylase activity of 14%. Mutation analysis showed a heterozygous mutation for G188fs (c.561delA) in the OTC gene. In contrast, mutation analysis of the OTC gene in her mother was unremarkable. Despite undoubted clinical and biochemical evidence for severe acute liver failure, histological evaluation of the explanted liver showed only mild to moderate abnormalities. Three weeks after admission, the child was discharged from the hospital in good condition and on a normal diet. Eight years after transplantation, the patient is doing well and liver function is normal, plasma amino acids and ammonia concentrations remained constantly normal.

Patient 2: Neonatal-/early-onset male OTCD. The following is a summary of a case of a previously reported boy (20). This male patient weighed 3250 g at birth and was delivered after an uncomplicated pregnancy at term by cesarean section. An older brother had died in the neonatal period at day 6 following an illness attributed to neonatal sepsis. His condition at birth was excellent, and he received routine infant care. He thrived until the third day of life, when he was noted to feed slowly. Several hours later, grunting and inspiratory retractions developed, and he became unresponsive to stimulation. There was profuse perspiration over his head and neck, and the rectal temperature was 35.5°C. In view of the identical history of illness in his previous male sibling, a detailed laboratory survey was initiated, including blood ammonia, which was estimated at 860 µmol/L. There was no evidence of generalized hepatic impairment. The child deteriorated rapidly and died. Absent ornithine transcarbamylase activity was found in his liver.

Biological basis

Etiology and pathogenesis

This disorder is caused by a partial or complete deficiency of ornithine transcarbamylase, the second enzyme in the urea cycle.

Ammonia detoxification

It is a mitochondrial enzyme composed of three identical subunits each with a molecular weight of 36kD (47). The gene encoding ornithine transcarbamylase is located on the short arm of the X-chromosome at band 21.1 (62), and it has been cloned and sequenced (41).

Ornithine transcarbamylase deficiency is inherited as an X-linked trait. Hemizygous males presenting in the newborn period have virtually no ornithine transcarbamylase activity in liver. The remainder of affected males, and some of the heterozygous females presenting later in life, have some residual enzyme activity (10). These individuals generally have 5% to 30% of normal ornithine transcarbamylase activity. However, there is uncertainty about the impact of functional data on clinical long-term outcome variables. Whereas an analysis of females with ornithine transcarbamylase deficiency found no clear genotype-phenotype correlation based on a large cohort of individuals (32). For male individuals with OTC-D, a genotype-phenotype relation between the onset time, the severity, and the underlying pathogenic variant was observed (54). In-depth analysis applying a newly established monoallelic in vitro expressions system found a correlation between the residual enzymatic OTC activity of male individuals and relevant clinical long-term outcome parameters, offering the potential for early and precise prediction of phenotypic severity (94). Moreover, a yeast growth assay has been developed to evaluate the pathogenicity of (unknown) OTC variants in a high-throughput manner (63).

Rarely, a balanced translocation involving an X chromosome in a female can result in the deletion of the OTC locus and cause consistent, non-random inactivation of the X-chromosome with the normal OTC gene leading to complete OTC deficiency and severe phenotype in a female (121). Approximately 560 disease-causing mutations (110; 05) have been described in patients. Frequently, the mutation appears de novo in female, and sometimes in male patients, and the mother is often not a disease-carrier (37). Generally, mutations causing neonatal disease affect amino acid residues that are in the interior of the enzyme, especially near the active site, whereas those associated with late-onset and milder phenotypes tend to be located on the surface of the protein (112). Conventional mutation analysis methods detect mutations in approximately 80% of patients with a clinical diagnosis of OTCD (67; 37). In approximately half of the patients in whom no mutation is identified by conventional methods, microarray analysis detects large deletions or rearrangements involving the OTC locus (98). Nowadays diagnosis is confirmed through molecular studies more frequently than through enzymatic activity (67; 87).

There are several disease genes very close to the OTC locus, including the Duchenne muscular dystrophy gene and the chronic granulomatous disease gene. Patients with these large deletions may have up to five severe genetic diseases making them extremely difficult to manage (25).

Neuropathologic changes in neonates dying of hyperammonemic coma involve intracerebral hemorrhage, prominent cerebral edema, and generalized neuronal cell loss (27). In survivors of prolonged hyperammonemic coma, changes observed on neuroimaging studies obtained months later include ventriculomegaly with increased sulcal markings, bilateral symmetrical low-density white matter defects, and diffuse atrophy with sparing of the cerebellum (69; 21). Neuropathology in those children who subsequently died was consistent with the neuroimaging findings and included ulegyria, cortical atrophy with ventriculomegaly, and prominent cortical neuronal loss (18), which, according to a study, occurred especially in the cingulate gyrus and insular cortex, with sparing of the perirolandic and occipital cortices (105).

Mechanisms of ammonia-induced brain damage in ornithine transcarbamylase deficiency are only partly understood. Ammonia is normally detoxified in astrocytes by glutamate dehydrogenase and glutamine synthetase. The accumulation of ammonia and glutamine has a number of toxic effects on the brain, including depletion of intermediates of cell energy metabolism and of organic osmolytes, the disaggregation of microtubules, altered amino acid and neurotransmitter concentrations, and alteration in water and potassium homeostasis (60; 60). Nitric oxide concentrations were found to be low in plasma and urine of females with ornithine transcarbamylase deficiency raising the possibility that reduced nitric oxide synthesis (due to reduced arginine synthesis) has a role in brain pathophysiology (73). Animal studies provided evidence for forebrain cholinergic neuronal loss in congenital ornithine transcarbamylase deficiency (19). Neurotransmitter alterations have been explored and altered serotonin metabolism has been put forward to explain some of the unusual behavior patterns, including anorexia and sleep abnormalities (44). Hepatic pathology investigations show diffuse microvesicular steatosis, periportal nuclear glycogen, variable portal fibrosis, and inflammation with occasional portal-to-portal bridging (106).

A zebrafish model was used to analyze the effects of hyperammonemia, demonstrating strongly enhanced transamination-dependent formation of osmolytic glutamine and excitatory glutamate, thereby inducing neurotoxicity and death via synergistically resulting in overactivation of NMDA receptors and bioenergetic impairment induced by depletion of 2-oxoglutarate. Withdrawal of 2-oxoglutarate from the tricarboxylic acid (TCA) cycle with consecutive tricarboxylic acid cycle dysfunction ultimately causes impaired oxidative phosphorylation with ATP shortage, decreased ATP/ADP-ratio, and elevated lactate concentrations. Interestingly, in zebrafish, inhibition of ornithine aminotransferase is a promising and effective therapeutic approach for preventing neurotoxicity and mortality by hyperammonemia (122; 123).

Diagnostic workup

In ornithine transcarbamylase deficiency, the principal biochemical feature is hyperammonemia. The most common inborn errors of metabolism that can present as a catastrophic illness in the newborn period are urea cycle disorders, organic acidemias, fatty acid oxidation disorders, mitochondriopathies, and maple syrup urine disease. Of these, only maple syrup urine disease is consistently associated with normal plasma ammonia concentrations.

In organic acidemias (methylmalonic acidemia, propionic acidemia, isovaleric acidemia, glutaric acidemia type II, and multiple carboxylase deficiency), marked metabolic acidosis, ketosis, and an increased anion gap can be found. Hypoglycemia and pancytopenia may also be present. Acylcarnitine profiles by tandem mass spectrometry from simple blood spots, collected on a Guthrie card or plasma, identify disease-characteristic acylcarnitines, gas chromatography-mass spectrometry of urine diagnostic organic acids. Plasma, but not CSF, amino acids may show an elevated glycine concentration.

Fatty acid oxidation defects present with hypoglycemia, decreased ketones, and increased free fatty acids. Acylcarnitine analyses reveal disease-specific profiles. Urinary organic acids often detect dicarboxylic aciduria, which is less sensitive than blood acylcarnitine profiling.

Congenital lactic acidosis or mitochondriopathies can be the result of a genetic defect in pyruvate metabolism or the mitochondrial respiratory chain. The principal biochemical finding is lactic acidosis. In primary defects of pyruvate metabolism, the ratio of lactate to pyruvate is usually between 10 to 1 and 20 to 1, whereas in secondary lactic acidosis (shock, sepsis, heart failure) and mitochondrial defects, this ratio is significantly increased.

These findings are in contrast to inborn errors of urea synthesis, including ornithine transcarbamylase deficiency, where acylcarnitine profiles and urinary organic acid profiles are normal and plasma lactate concentration is normal to mildly increased. In other inborn errors of metabolism, elevated peak-blood ammonia concentration is generally in the range of 150 to 500 µmol/L (normally 15 to 40 µmol/L). In neonatal-onset urea cycle disorders, however, peak-blood ammonia concentration is likely to increase above 500 up to 5000 µmol/L.

Plasma amino acid patterns are distinct within the urea cycle disorders, with elevated concentrations of glutamine, alanine, and asparagine and low concentrations of arginine and ornithine, and abnormal citrulline (113). Citrulline is the product of carbamoyl phosphate synthetase 1 and ornithine transcarbamylase activity and the substrate for argininosuccinic synthetase and argininosuccinic lyase.

Ammonia detoxification

Thus, the concentration of citrulline is absent or markedly reduced in carbamoyl phosphate synthetase 1 and ornithine transcarbamylase deficiencies but markedly elevated in citrullinemia and argininosuccinic aciduria. This contrasts with transient hyperammonemia of the newborn, which is not associated with a congenital urea cycle defect and has normal glutamine, arginine, as well as normal or only slightly elevated citrulline concentrations. Differentiation of carbamoyl phosphate synthetase from ornithine transcarbamylase deficiency depends on detecting excessive urinary orotic acid excretion in ornithine transcarbamylase deficiency and decreased or normal excretion in carbamoyl phosphate synthetase 1 deficiency. A deficiency of N-acetylglutamate synthase, the enzyme needed for the production of the cofactor (N-acetylglutamate) for carbamoyl phosphate synthetase 1 is also associated with low-normal orotic acid excretion. Very similar is finally the mitochondrial carbonic anhydrase VA deficiency, which is also associated with low-normal orotic acid excretion (115).

Diagnosis of ornithine transcarbamylase deficiency in older children and adults with partial deficiencies may be less straightforward than in neonatal cases. The plasma ammonia concentration may be in the range of 150 to 250 µmol/L rather than above 500 µmol/L during symptomatic episodes and normal when the individual is clinically stable. Arginine and citrulline concentrations are often low normal in partial ornithine transcarbamylase deficiency rather than absent to trace as in a complete defect. Orotic aciduria can be provoked by an allopurinol loading test (39). It is reliable for identifying carriers with severe mutations but may be less reliable in milder variants. A subsequent study confirmed the high sensitivity of the test but documented a much lower specificity (34). The diagnosis of ornithine transcarbamylase deficiency is best confirmed by DNA studies in blood. Molecular genetic analysis is currently used more often in North America and Europe to confirm diagnosis than measurement of enzymatic activity (87). In vivo assays of residual urea synthetic capacity have also been developed (93; 81). This involves the oral or intravenous administration of stable isotope (nitrogen-15 or carbon-13) ammonia, glutamine, or sodium acetate and the subsequent measurement by mass spectrometry of labeled urea and glutamine synthesized. These methods may have the potential to differentiate urea cycle disorder patient subgroups and may be helpful in monitoring novel therapies for urea cycle disorders (81).

Management

For a detailed discussion see “Suggested guidelines for the diagnosis and management of urea cycle disorders” (37).

Management of acute hyperammonemia in OTCD.

Table 1. Protein, Liquid, and Glucose Management

Escalation Level	NH3 (µmol/L)	Protein	Liquid IV (ml/kg/d)	Glucose IV (mg/kg/min)	Insulin	Comments*****
1	< 100	Stop*	100 - 150**	10***	i.n.****	/
2	100 - 250	Stop*	100 - 150**	10***	i.n.****	Inform metabolic clinic
3	250 - 500	Stop*	100 - 150**	10***	i.n.****	Inform dialysis clinic
4	> 500	Stop*	100 - 150**	10***	i.n.****	Hemodialysis
Consensus-based treatment protocol for pediatric (specialized) hospitals treating OTCD patients with acute hyperammonemia according to “Suggested guidelines for the diagnosis and management of urea cycle disorders” (37). Stop protein intake for 24 hours (maximum 48 hours) Liquid management might be adapted to hospital- and age-specific requirements Glucose management might be adapted to age-specific requirements If necessary (i.n.) give 0.05 units/kg/h ***Hyperglycemia can be dangerous; monitor glucose every 0.5 to 1 hour; monitor blood ammonia concentrations every 3 hours; monitor electrolytes, blood gases, and lactate regularly, eg, every 3 hours

Table 2. First-Line Medication for OTCD****

Escalation Level	NH3 (µmol/L)	Sodium benzoate IV***		Sodium benzoate/-phenylacetate (Ammonul ®) IV***		L-Arginine hydro-chloride 21% IV***		Carbamoyl-glutamate by mouth
Escalation Level	NH3 (µmol/L)	Bolus (mg/kg) in 90 – 120 min	Maintenance (mg/kg/d)**	Bolus (mg/kg) in 90 – 120 min	Maintenance (mg/kg/d)**	Bolus (mg/kg) in 90 – 120 min	Maintenance (mg/kg/d)	Carbamoyl-glutamate by mouth
1	< 100	/	/	/	/	/	/	/
2	100 - 250	250	250 – 500 5.5 g/m²/d*	250	250 – 500	250 – 400	250	/
3	250 - 500	250	250 – 500 5.5 g/m²/d*	250	250 – 500	250 – 400	250	/
4	> 500	250	250 – 500 5.5 g/m²/d*	250	250 – 500	250 – 400	250	/
Consensus-based treatment protocol for pediatric (specialized) hospitals treating OTCD patients with acute hyperammonemia according to “Suggested guidelines for the diagnosis and management of urea cycle disorders” (37). If patient weighs more than 20 kg If on dialysis maintenance dose should be increased to 350 mg/kg/d First-line medications must be diluted in 10% glucose prior to intravenous application; (Caution: L-Arginine-HCl may cause metabolic acidosis and extravasation may lead to tissue necrosis) **Control electrolytes due to possible danger of hypernatremia and hypokalemia

In the newborn period, management of acute hyperammonemia may be anticipatory or reactive. In families who have had an index patient, the birth of an at-risk or prenatally diagnosed infant provides the opportunity for prospective management. Within hours after birth, the child can be placed on oral therapy with appropriate ammonia scavengers and amino acids as subsequently described.

For newborns or infants who have been diagnosed during hyperammonemia or coma, therapy must not be delayed because coma duration of fewer than 1.5 days (83) and timely start of treatment are crucial determinants of outcome. In fact, current knowledge proposes that noninterventional variables, such as disease onset and initial peak-blood ammonia concentration, are of utmost importance for the neurologic outcome of individuals with urea cycle disorders (86). Large ongoing studies from the E-IMD and UCDC consortia aim to investigate the effects of (early) diagnosis and current treatment principles on the neurologic and cognitive outcome of affected individuals. Specialized pediatric hospitals should have first-line medications and consensus-based treatment protocols, and they must act according to the following principles:

(1) Stop protein intake (see Table 1)
(2) Start intravenous fluid and glucose substitution (see Table 1)
(3) Start first-line medication (see Table 2)

Suggestions for a consensus-based treatment protocol, following the above-outlined principles, are depicted in Tables 1 and 2. Each (specialized) pediatric hospital should be able to adapt these recommendations to facility-specific conditions to provide best-care medicine for their patients and prevent delay of treatment.

Ammonia scavengers (sodium benzoate, sodium phenylacetate/-butyrate) provide alternate pathways to eliminate waste nitrogen (14). A few studies demonstrate that treatment with sodium benzoate and sodium phenylbutyrate is safe and effective for the treatment or prevention of hyperammonemia in urea cycle disorders (43; 12). Sodium benzoate is conjugated with glycine to form hippurate, and sodium phenylbutyrate is conjugated with glutamine to form phenylacetylglutamine, both of which are cleared by the kidneys. Glutamine contains two nitrogen atoms. Thus, two moles of waste nitrogen are removed for each mole of phenylacetate/-butyrate administered. Theoretically, on a mole-per-mole basis, nitrogen-disposing efficacy of sodium phenylbutyrate should be twice that of sodium benzoate, and although biochemical superiority of sodium phenylbutyrate has been demonstrated (72), no systematic studies regarding the effects of long-term pharmacotherapy on neurologic or cognitive outcome, as defined by clinical endpoints, exists thus far.

Currently, a multicenter, randomized, double-blind, placebo-controlled trial of Carbaglu® in North America investigates if this drug is helpful for individuals suffering from ornithine transcarbamylase deficiency with regard to 1) improved neurocognitive outcome and 2) more rapid reduction of ammonium concentrations, improved function, and shortened hospitalization compared to standard therapy alone (01).

Energy should be constantly supplemented via oral, nasogastric, or intravenous routes by 20% to 100% above the recommended daily requirements using carbohydrates (such as glucose orally or dextrose 20% orally or glucose intravenously) and fat (intralipid 20%) starting at 1 g/kg and increased up to 3 g/kg per day. However, a multicenter study showed that during the first 24 hours of emergency treatment, caloric intake was lower than during maintenance treatment and was below age-adapted recommendations (86). Carbohydrates were the primary, if not sole, energy source, whereas fats were often omitted from initial emergency treatment. Soluble insulin is provided to support intracellular glucose uptake and to avoid hyperglycemia. The intake of natural protein is stopped for 24 hours to maximally 48 hours and is then reintroduced gradually as tolerated (42). In the event that ammonia concentrations do not respond to this conservative management, and biochemical or clinical symptoms worsen, continuous venovenous hemodiafiltration (CVVHDF) must be started immediately (planned and organized early, ie, at concentrations greater than 400 µmol/L) in neonates or children with ammonia concentrations of greater than 500 µmol/L (see Table 1) or at lower concentrations if response to medical treatment is inadequate. Notably, even though continuous venovenous hemodiafiltration is the optimal modality for extracorporal ammonia detoxification (83), prognosis is not related to dialysis modality, but primarily to the duration of coma before the start of treatment, confirming the necessity for rapid and aggressive management. In fact, a retrospective data analysis of 202 published cases revealed that current practice of dialysis does not affect outcomes. Only 20% of all investigated individuals had a normal clinical outcome. In conclusion, dialysis along with conservative pharmacotherapeutic treatment is recommended to be initiated as early as possible and at even lower concentrations of ammonium (40); however, long-term data analyzing these recommendations are not available.

The dietary aim is to minimize external protein (and, thus, nitrogen) intake and at the same time to prevent endogenous protein catabolism by meeting high-energy demands of the patient. The initial dietary emergency regimen should be protein-free, but protein or essential amino acids must be reintroduced after 24 to 48 hours or once blood ammonia concentration has fallen below 100 µmol/L (37). In addition to close-meshed control of laboratory parameters like ammonia, electrolytes, glucose, etc., plasma amino acids must be determined and the results must be available daily to safely adjust management. The reduction of protein intake must be carefully monitored to prevent over-restriction. A diet with inadequate intake can impair protein synthesis and lead to catabolic metabolic decompensation or failure to thrive (42).

According to the physician’s advice, an oral dietary emergency regimen might be applicable to treat milder hyperammonemic episodes, as long as the patient is not at risk of developing catabolism due to insufficient energy supply as a consequence of vomiting, loss of appetite, or diarrhea. Protein-, liquid-, and glucose management is identical to the protocol in Table 1.

Patients and families might start with an oral emergency dietary regimen at home. Antipyretic measurements must be consequently carried out if temperature exceeds 38°C; however, patients and parents must be aware that these measures must not postpone or replace adequate emergency treatment in the hospital (42; 126).

Patients should be supplied with an emergency card, letter, or bracelet containing instructions for emergency measures and phone numbers. Logistics of rational therapeutic measures should be repeatedly evaluated by the specialist team with the family and the primary care physicians.

Long-term management of OTCD.

Table 3. Long-Term Medication for OTCD

	Sodium benzoate by mouth	Sodium phenylbutyrate by mouth*		L-Arginine by mouth***		L-Citrulline by mouth***	Carbamoyl-glutamate by mouth
	(in mg/kg/d)**	< 20 kg (in mg/kg/d)**	> 20 kg (in g/m2/d)**	< 20 kg (in mg/kg/d)	> 20 kg (in g/m²/d)
Dose	≤ 250	≤ 250	5	100 -- 200	2.5 -- 6	100 - 200	/
Maximum	12 g/d	12 g/d		6 g/d		6 g/d	/
Consensus-based long-term treatment protocol for pediatric (specialized) hospitals treating patients with OTCD according to “Suggested guidelines for the diagnosis and management of urea cycle disorders” (37). Second choice that should be given together with sodium benzoate in patients in which benzoate alone is not enough. In some patients higher doses may be needed (< 20 kg: 450 – 600 mg/kg/d and > 20 kg: 9.9 – 13 g/m²/d for sodium phenylbutyrate). **L-Citrulline may be preferable instead of L-arginine

Long-term management of ornithine transcarbamylase deficiency relies on the goals of preventing recurrent hyperammonemia and neurologic sequelae and improving quality of life by the following principles (42; 37):

(1) Long-term medication (see Table 3)
(2) If individually necessary, avoidance of catabolism
(3) Suitable emergency regimens in intercurrent illness (see Tables 1 and 2)

Catabolism must be avoided as much as possible. In addition to intercurrent illnesses, especially if associated with high fever and decreased intake of food and fluids, dangerous triggers are severe exercise, seizures, trauma or burns, steroid administration, chemotherapy, and gastrointestinal hemorrhage.

Dietary treatment is an essential anchor point of long-term management and requires the knowledge of a specialist metabolic dietitian. For infants and older children, nutritional management involves the use of a high-caloric, low-protein diet supplemented with essential amino acids and, if necessary, vitamins and minerals. This is most readily accomplished by using small amounts of natural protein, an essential amino acids formula, and supplemental calories provided by a special formula that does not contain protein. The goal of long-term management is based on minimizing the nitrogen load on the urea cycle. The FAO/WHO/UNO 2007 report (37) can be used as age- and gender-dependent recommendations for energy intakes. Especially in young infants and children, fasts should be avoided and snacks given to reduce the possibility of (overnight) catabolism.

Dietary measures are very important for safely steering the conservative management in urea cycle disorders; however, growth impairment is a common and considerable burden for affected individuals (51). It was unknown thus far, if and to which extent a protein-controlled or protein-reduced diet does iatrogenically contribute to growth retardation in urea cycle disorders. A study showed that growth impairment was determined by disease severity and associated with reduced or borderline plasma branched-chain amino acid concentrations but was not associated with the degree of natural protein restriction (88), which is important for the consultation and reassurance of the affected urea cycle disorders individual.

Periodic measurement of plasma amino acids, which includes glutamine, and blood ammonia may permit adjustment of therapy before clinical symptoms appear. Long-term medication comprises the use of sodium benzoate and sodium phenylbutyrate as well as the essential amino acids L-arginine or L-citrulline. A detailed overview is provided in Table 3. Drugs may not be well tolerated by the child or family. Sodium phenylbutyrate tastes and smells unpleasant and may be irritating to the stomach.

Glycerol phenylbutyrate (RAVICTI®) has the same mechanism of action as sodium phenylbutyrate but is a sodium- and sugar-free prepro-drug of phenylacetic acid that has little odor or taste. Phenylbutyrate may deplete branched-chain amino acid concentrations and cause menstrual dysfunction/amenorrhea in up to 25% of postpubertal females (17; 37). Acute toxicity of benzoate and phenylbutyrate has been rare, but severe overdoses (2 to 10 times recommended) have led to symptoms that may be clinically mistaken for hyperammonemic episodes, including lethargy, hyperventilation, metabolic acidosis, cardiopulmonary collapse, and death (09; 85). To avoid complications, eg, mucositis or gastritis, sodium benzoate and sodium phenylbutyrate should be administered several times daily during meals with abundant fluids (37). In addition, supplementations of L-arginine or L-citrulline as essential amino acids aim at maximizing ammonia excretion through the urea cycle (13). For long-term treatment, sodium benzoate is used more often than sodium phenylbutyrate in both male and female patients with ornithine transcarbamylase deficiency, whereas L-arginine and L-citrulline are used with equal frequency (86).

Plasma carnitine deficiency may develop in patients with urea cycle disorder who are on a low-protein diet or receive treatment with ammonia scavengers. Carnitine supplementation (50-100 mg/kg/d) can be helpful in such conditions (80). Neomycin, colistin, and metronidazole have formerly been put forth as means of decreasing intestinal ammonia in hepatic encephalopathy; however, there is still no good evidence to support this use and pharmacological gastrointestinal decontamination is only sporadically used (86; 37). The benefit of vaccinations outweighs the risk of decompensations. They are recommended at the same schedule as for healthy children (68; 37).

By now a significant number of patients with various urea cycle disorders have received partial or total orthotopic liver transplants to provide enzyme replacement therapy (119; 71). In all successful cases, this procedure has cured hyperammonemia and permitted a normal protein intake. However, its effectiveness is hampered by expense, limited availability of donor organs, and significant morbidity from complications of transplantation or immunosuppression. Long-term survival is over 95% in proximal urea cycle disorders. Liver transplantation does not normalize citrulline concentration, which is primarily produced in the gut; thus, following transplantation, supplementation with citrulline or arginine may need to be continued (109).

Ideally, in patients with severe neonatal-onset disease, in patients with progressive liver disease, or in patients suffering from recurrent sever decompensations despite intensive medical treatment, orthotopic liver transplantation should be carried out between (3 to) 6 and 12 months of age before irreversible neurologic damage has occurred (37). A retrospective survey study investigated if patients would profit from liver transplantation by preventing further recurrent decompensations. Individuals with urea cycle disorders had an improved neurocognitive outcome if they received a liver graft, suggesting they should undergo liver transplantation after comparatively low maximum ammonium concentrations in order to protect the patient’s neurocognitive abilities (53; 52). However, patients with urea cycle disorder receiving a liver transplant are mainly between 1 and 6 years of age. An analysis evaluating the outcome of pediatric and adult patients with urea cycle disorder who underwent liver transplantation showed that approximately two thirds were transplanted before 5 years of age and that ornithine transcarbamylase deficiency was the most common urea cycle disorder in pediatric and adult patients receiving a new liver (120). Overall 1-, 5-, and 10-year survival was excellent, with 93%, 89%, and 87% survival, respectively. Two analyses, including one study from the United Network for Organ Sharing database comprising all pediatric urea cycle disorders candidates receiving liver transplantation between 2002 and 2020, found that delayed transplantation was associated with a long-term risk of cognitive delay and that early liver transplantation may prevent progressive neurologic injury and optimize cognitive outcomes (89; 124). However, further data suggest limited impact of liver transplantation on the neurodevelopmental outcomes of individuals with a severe disease burden (50).

Some medications are contraindicated in urea cycle disorders because of secondary inhibition of the urea cycle or inducing catabolism, most importantly valproic acid, which inhibits NAGS (03). Even in well-controlled and managed patients, peracute deadly coma can occur. Systemic steroid treatment can have the same result. Less often, but also to be considered, is the potential development of hyperammonemic crises by the treatment with carbamazepine, the use of asparaginase or 5-fluorouracil in cancer therapy, or bladder, uterine, or joint irrigation with glycine solution during surgery.

Hepatocyte transplantation is an interesting therapeutic option being investigated for patients with urea cycle disorder who are waiting for liver transplantation (70). New (genetic) therapies might become an option in the near future (24; 26). Intravenous application of an AAV-vector harboring human codon-optimized OTC gene showed no adverse clinical events, predominant hepatic biodistribution, and sustained supra-physiological OTC overexpression in OTC-deficient cynomolgus monkeys (08).

Another interesting approach for the treatment of acute hyperammonemia is inhibition of ornithine aminotransferase, leading to transamination-dependent decrease of glutamate and glutamine. Mammalian transfer will provide more insight into determining if this approach is indeed a potential new therapeutic principle for individuals with urea cycle disorders (122). Lately, it has been suggested that autophagy cooperates with the urea cycle in ammonia homeostasis. Selective activation of hepatic autophagy might, therefore, be used to treat hyperammonemia due to acquired or inherited diseases. However, it remains to be elucidated if autophagy also plays an important role during hyperammonemic conditions in the brain in order to determine if autophagy is a suitable target for treatment of hyperammonemic conditions (100).

Outcomes

Prior to the development of alternate pathway therapy using ammonia scavengers (eg, sodium benzoate, sodium phenylacetate/-butyrate), virtually all children with neonatal ornithine transcarbamylase deficiency died in the newborn period or during infancy. Between the 1980s and mid-1990s, nearly all children with early-onset type ornithine transcarbamylase deficiency still died during the initial episode (114). This, however, has slowly changed with the widespread availability of ammonia measurement in hospitals, growing knowledge about the disease, and the use of alternate pathway therapy. Survival rates for patients with early-onset and late-onset ornithine transcarbamylase deficiency have significantly improved (male neonatal-onset OTCD: approximately 85%; male late-onset OTCD: > 95%; female late-onset OTCD: > 95%) (49). In contrast, a review and metaanalysis showed less convincing results, indicating no improvement in survival of urea cycle disorders over more than 3 decades, between 1978 and 2014 (16). Furthermore, additional studies demonstrated that noninterventional variables reflecting disease severity, such as disease onset and initial peak-blood ammonia concentration, are associated with the highest risk of mortality and poor neurologic outcome (28; 86). Growth retardation is not affected by high initial peak-blood ammonia concentration; however, 32% of male and 52% of female patients over 1 year of age with ornithine transcarbamylase deficiency were below the tenth percentile for height (75). Growth retardation is rather associated with high intrinsic disease severity and reduced plasma branched-chain amino acid levels (88).

Long-term morbidity is still substantial in patients with urea cycle disorder. Cognitive outcome is better in prospectively treated infants and in children with partial defects (65; 74). It could be shown that females with partial ornithine transcarbamylase deficiency had IQ scores in the low average range that remained stable during 5-year follow-up on alternate pathway therapy (64). Overall, 50% of patients with urea cycle disorders suffer from intellectual disability (57). A study on individuals with ornithine transcarbamylase deficiency showed that intellectual impairment is global rather than domain-specific (15). Whereas Bachmann suggests that neurocognitive outcome does essentially depend on the initial and peak-blood ammonia concentration (07), investigations show that cognitive outcome does inversely correlate with the height of initial peak-blood ammonia concentration in proximal rather than distal urea cycle disorders (89).

Considering proximal urea cycle disorders in expanded newborn screening is an interesting approach; however, citrulline and glutamine alone are not specific, although early identification and, thus, a potential attenuation of the initial decompensation might open the possibility for an improved clinical outcome (87; 116). Combined levels of orotic acid and citrulline in routine newborn screening might enhance the detection of proximal urea cycle disorders in newborn screening and could possibly foster the discussion on screening for proximal urea cycle disorders in routine newborn screening in the future (101).

Special considerations

Pregnancy

The puerperium in ornithine transcarbamylase-deficient heterozygotes has been repeatedly associated with hyperammonemic crises (04). Langendonk studied a series of pregnancies in women with inherited metabolic diseases and suggested that special care must be taken not to confuse behavioral changes of hyperammonemia for symptoms of postpartum psychosis or depression (59). Because late-onset disease manifestation of urea cycle disorders appears to comprise more than 50% of all urea cycle disorders (77; 102; 76; 55) and because there is a high possibility for missing cases presenting with symptoms of postpartum psychosis, depression, or severe mood disorder, routine monitoring of plasma ammonia concentrations in those women was suggested (29). A special risk period for acute hyperammonemic decompensation is between 3 to 14 days postpartum. The relative metabolic stress during this episode is thought to be due to changes of the puerperium and an increased protein load following involution of the uterus (59; 37). Additionally, nausea and vomiting during pregnancy might lead to severe problems because of catabolism and, thus, should always be taken seriously and treated effectively with antiemetics. Pregnancy in women with ornithine transcarbamylase deficiency should, therefore, be monitored and escorted in close contact with a metabolic center (59).

Anesthesia

There has been one report of hyperammonemia induced by enflurane in argininosuccinic aciduria (06). It is prudent to use anesthetics with low toxicity to the liver. In addition, surgery requires the stopping of oral medication and may be associated with a catabolic condition, both of which may induce hyperammonemia in ornithine transcarbamylase deficiency. Therefore, it is important to provide alternate pathway therapy intravenously until the patient is able to tolerate oral medication. The patient must receive adequate glucose to reduce catabolic stress. One report of two siblings with severe ornithine transcarbamylase deficiency describes the perioperatively uneventful use of midazolam, s-ketamine, fentanyl, and isoflurane with local injection of ropivacaine along with intravenous infusion of glucose and alternate pathway drugs (97). Surgery should only be carried out in centers prepared for dealing with acute hyperammonemic episodes. After surgery, close monitoring of the clinical status and ammonia and glutamine concentrations as well as shifting to oral medications and diet are required (37). A case was reported emphasizing that appropriate guidelines for the pre- and postoperative care of patients with inherited metabolic diseases of the urea cycle are indispensable (30).

References

01: Ah Mew N, Cnaan A, McCarter R, et al. Conducting an investigator-initiated randomized double-blinded intervention trial in acute decompensation of inborn errors of metabolism: Lessons from the N-Carbamylglutamate Consortium. Transl Sci Rare Dis 2018;20;3(3-4):157-70. PMID 30613471
02: Ah Mew N, Krivitzky L, McCarter R, et al. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. J Pediatr 2013;162(2):324-9. PMID 22901741
03: Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 2011;55(2):426-34. PMID 21147182
04: Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. N Engl J Med 1990;322:1652-5. PMID 2342525
05: Arranz JA, Riudor E, Marco-Marin C, Rubio V. Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential. J Inherit Metab Dis 2007;30:217-26. PMID 17334707
06: Asai K, Ishii S, Ohta S, Furusho K. Fatal hyperammonaemia in argininosuccinic aciduria following enflurane anaesthesia. Eur J Pediatr 1998;157:169-70. PMID 9504797
07: Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr 2003;162(6):410-6. PMID 12684900
08: Baruteau J, Cunningham SC, Yilmaz BS, et al. Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Mol Ther Methods Clin Dev 2021;23:135-46. PMID 34703837
09: Batshaw ML, Brusilow S, Waber L, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med 1982;306:1387-92. PMID 7078580
10: Batshaw ML, Msall M, Trojak J. The risk of serious illness in carriers of ornithine transcarbamylase deficiency. J Pediatr 1986;108:236-41. PMID 3944708
11: Ben-Ari Z, Dalal A, Morry A, et al. Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. J Hepatol 2010;52(2):292-5. PMID 20031247
12: Berry SA, Longo N, Diaz GA, et al. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2 months to 2 years. Mol Genet Metab 2017;122(3):46-53. PMID 28916119
13: Brusilow SW. Arginine, an indispensable amino acid for patients with inborn errors of urea synthesis. J Clin Invest 1984;72:2144. PMID 6511918
14: Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science 1980;207(4431):659-61. PMID 6243418
15: Buerger C, Garbade SF, Dietrich Alber F, et al. Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain-specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events. J Inherit Metab Dis 2019;42(2):243-53. PMID 30671983
16: Burgard P, Kölker S, Haege G, Linder M, Hoffmann GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders--review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis 2016;39:219-29. PMID 26634836
17: Burrage LC, Jain M, Gandolfo L, et al. Sodium phenylbutyrate decreases plasma branched –chain amino acids in patients with urea cycle disorders. Mol Genet Metab 2014;113(1-2):131-5. PMID 25042691
18: Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis 1998;21(Suppl 1):6-20. PMID 9686341
19: Butterworth RF. Evidence for forebrain cholinergic neuronal loss in congenital ornithine transcarbamylase deficiency. Metab Brain Dis 2000;15:83-91. PMID 10885542
20: Campbell AG, Rosenberg LE, Snodgrass PJ, Nuzum CT. Ornithine transcarbamylase deficiency: a cause of lethal neonatal hyperammonemia in males. N Engl J Med 1973;288(1):1-6. PMID 4681895
21: Choi CG, Yoo HW. Localized proton MR spectroscopy in infants with urea cycle defect. AJNR Am J Neuroradiol 2001;22(5):834-7. PMID 11337324
22: Christodoulou J, Qureshi IA, McInnes RR, Clarke JT. Ornithine transcarbamylase deficiency presenting with strokelike episodes. J Pediatr 1993;122:423-5. PMID 8441099
23: Crosbie DC, Sugumar H, Simpson MA, Walker SP, Dewey HM, Reade MC. Late-onset ornithine transcarbamylase deficiency: a potentially fatal yet treatable cause of coma. Crit Care Resusc 2009;11(3):222-7. PMID 19737127
24: Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther 2009;17(8):1340-6. PMID 19384294
25: Deardorff MA, Gaddipati H, Kaplan P, et al. Complex management of a patient with a contiguous Xp11.4 gene deletion involving ornithine transcarbamylase: a role for detailed molecular analysis in complex presentations of classical diseases. Mol Genet Metab 2008;94(4):498-502. PMID 18524659
26: De Sabbata G, Boisgerault F, Guarnaccia C, et al. Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. Mol Ther Methods Clin Dev 2020;20:169-80. PMID 33473356
27: Drogari E, Leonard JV. Late onset ornithine carbamoyl transferase deficiency in males. Arch Dis Child 1988;63:1363-7. PMID 3202644
28: Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007;356(22):2282-92. PMID 17538087
29: Fassier T, Guffon N, Acquaviva C, D'Amato T, Durand DV, Domenech P. Misdiagnosed postpartum psychosis revealing a late-onset urea cycle disorder. Am J Psychiatry 2011;168(6):576-80. PMID 21642480
30: Gharavifard M, Sabzevari A, Eslami R. Anesthetic management in a child with citrullinemia: a case report. Anesth Pain Med 2014;4(3):e21791. PMID 25289380
31: Gidal BE, Inglese CM, Meyer JF, Pitterle ME, Antonopolous J, Rust RS. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol 1997;16:301-5. PMID 9258962
32: Gobin-Limballe S, Ottolenghi C, Reyal F, et al. OTC deficiency in females: phenotype-genotype correlation based on a 130-family cohort. J Inherit Metab Dis 2021;44(5):1235-47. PMID 34014569
33: Gropman AL, Prust M, Breeden A, Fricke S, VanMeter J. Urea cycle defects and hyperammonemia: effects on functional imaging. Metab Brain Dis 2013;28(2):269-75. PMID 23149878
34: Grunewald S, Fairbanks L, Genet S, et al. How reliable is the allopurinol load in detecting carriers for ornithine transcarbamylase deficiency. J Inherit Metab Dis 2004;27:179-86. PMID 15159648
35: Gunz AC, Choong K, Potter M, Miller E. Magnetic resonance imaging findings and neurodevelopmental outcomes in neonates with urea-cycle defects. Int Med Case Rep J 2013;6:41-8. PMID 23983495
36: Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol 2004;55:80-6. PMID 14705115
37: Haberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis 2019;42(6):1192-230. PMID 30982989
38: Haberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn 2004;24(5):378-83. PMID 15164414
39: Hauser ER, Finkelstein JE, Valley D, Brusilow SW. Allopurinol-induced orotidinuria: a test for mutations at the ornithine carbamoyltransferase locus in women. N Engl J Med 1990;322:1641-5. PMID 2342523
40: Hediger N, Landolt MA, Diez-Fernandez C, Huemer M, Haberle J. The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders. J Inherit Metab Dis 2018;41(4):689-98. PMID 29520739
41: Horwich AL, Fenton WA, Williams KR, et al. Structure and expression of a complementary DNA for the nuclear coded precursor of human mitochondrial ornithine transcarbamylase. Science 1984;224:1068-74. PMID 6372096
42: Hoffmann GF, Zschocke J, Nyhan WL. Inherited metabolic diseases - a practical approach. Heidelberg: Springer, 2017.
43: Husson MC, Schiff M, Fouilhoux A, et al. Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study. Orphanet J Rare Dis 2016;11(1):127. PMID 27663197
44: Hyman SL, Porter CA, Page TJ, Iwata BA, Kissel R, Batshaw ML. Behavior management of feeding disturbances in urea cycle and organic acid disorders. J Pediatr 1987;111:558-62. PMID 2443629
45: Jamiolkowski D, Kölker S, Glahn EM, et al. Behavioural and emotional problems, intellectual impairment and health-related quality of life in patients with organic acidurias and urea cycle disorders. J Inherit Metab Dis 2016;39(2):231-41. PMID 26310964
46: Kalidas K, Behrouz R. Inherited metabolic disorders and cerebral infarction. Expert Rev Neurother 2008;8(11):1731-41. PMID 18986243
47: Kalousek F, Francois B, Rosenberg LE. Isolation and characterization of ornithine transcarbamylase from normal human liver. J Biol Chem 1978;253:3939-44. PMID 25896
48: Kamoun P, Kensom AH, Shin YS, et al. Prenatal diagnosis of the urea cycle diseases: a survey of the European cases. Am J Med Genet 1995;55:247-50. PMID 7717428
49: Kido J, Matsumoto S, Häberle J, et al. Long-term outcome of urea cycle disorders: report from a nationwide study in Japan. J Inherit Metab Dis 2021a;44(4):826-37.** PMID 33840128
50: Kido J, Matsumoto S, Häberle J, et al. Role of liver transplantation in urea cycle disorders: report from a nationwide study in Japan. J Inherit Metab Dis 2021c;44(6):1311-22. PMID 34232532
51: Kido J, Matsumoto S, Ito T, et al. Physical, cognitive, and social status of patients with urea cycle disorders in Japan. Mol Genet Metab Rep 2021b;27:100724. PMID 33614409
52: Kido J, Matsumoto S, Mitsubuchi H, Endo F, Nakamura K. Early liver transplantation in neonatal-onset and moderate urea cycle disorders may lead to normal neurodevelopment. Metab Brain Dis 2018;33:1517-23. PMID 29948653
53: Kido J, Matsumoto S, Momosaki K, et al. Liver transplantation may prevent neurodevelopmental deterioration in high-risk patients with urea cycle disorders. Pediatr Transplant 2017;21(6). PMID 28608518
54: Kido J, Sugawara K, Sawada T, et al. Pathogenic variants of ornithine transcarbamylase deficiency: nation-wide study in Japan and literature review. Front Genet 2022;13:952467. PMID 36303552
55: Kolker S, Cazorla AG, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis 2015a;38(6):1041-57.** PMID 25875215
56: Kolker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis 2015b;38(6):1059-74.** PMID 25875216
57: Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009;66(1):96-101. PMID 19287347
58: Laemmle A, Gallagher RC, Keogh A, et al. Frequency and pathophysiology of acute liver failure in ornithine transcarbamylase deficiency (OTCD). PLoS One 2016;11(4):e0153358. PMID 27070778
59: Langendonk JG, Roos JC, Angus L, et al. A series of pregnancies in women with inherited metabolic disease. J Inerhit Metab Dis 2012;35(3):419-24. PMID 21918856
60: Lichter-Konecki U. Profiling of astrocyte properties in the hyperammonaemic brain: shedding new light on the pathophysiology of the brain damage in hyperammonaemia. J Inherit Metab Dis 2008;31(4):492-502. PMID 18683079
61: Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. Glia 2008;56(4):365-77. PMID 18186079
62: Lindgren V, Martinville B, Horwich AL, Rosenberg LE, Francke U. Human ornithine transcarbamylase locus mapped to band Xp21.1 near the Duchenne muscular dystrophy locus. Science 1984;226:698-700. PMID 6494904
63: Lo RS, Cromie GA, Tang M, et al. The functional impact of 1,570 individual amino acid substitutions in human OTC. Am J Hum Genet 2023;110(5):863-79. PMID 37146589
64: Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-9. PMID 8778603
65: Maestri NE, Hauser ER, Bartholomew D, Brusilow SW. Prospective treatment of urea cycle disorders. J Pediatr 1991;119:923-8. PMID 1720458
66: Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide in the management of urea cycle disorders. J Pediatr 1992;121:259-61. PMID 1640294
67: Martín-Hernández E, Aldámiz-Echevarría L, Castejón-Ponce E, et al. Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases. Orphanet J Rare Dis 2014;9:187.** PMID 25433810
68: Morgan TM, Schlegel C, Edwards KM, et al. Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics 2011;127(5):e1147-53. PMID 21482610
69: Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis. N Engl J Med 1984;310:1500-5. PMID 6717540
70: Meyburg J, Opladen T, Spiekerkötter U, et al. Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders. J Inherit Metab Dis 2018;41(1):81-90.** PMID 29027067
71: Molema F, Martinelli D, Hörster F, et al. Liver and or kidney transplantation in amino and organic acid-related inborn error of metabolism: an overview on European data. J Inherit Metab Dis 2021;44(3):593-605.** PMID 32996606
72: Nagamani SCS, Agarwal U, Tam A, et al. A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers. Genet Med 2018;20:708-16. PMID 29693650
73: Nagasaka H, Komatsu H, Ohura T, et al. Nitric oxide synthesis in ornithine transcarbamylase deficiency: possible involvement of low no synthesis in clinical manifestations of urea cycle defect. J Pediatr 2004;145(2):259-62. PMID 15289781
74: Nagata N, Matsuda I, Matsuura T, et al. Retrospective survey of urea cycle disorders: part 2. Neurological outcome in forty-nine Japanese patients with urea cycle enzymopathies. Am J Med Genet 1991;40:477-81. PMID 1746614
75: Nakamura K, Kido J, Matsumoto S, Mitsubuchi H, Endo F. Clinical manifestations and growth of patients with urea cycle disorders. J Hum Genet 2016;61(7):613-6. PMID 26935171
76: Nakamura K, Kido J, Mitsubuchi H, Endo F. Diagnosis and treatment of urea cycle disorder in Japan. Pediatr Int 2014;56(4):506-9. PMID 25039902
77: Nassogne MC, Héron B, Touati G, et al. Urea cycle defects: management and outcome. J Inherit Metab Dis 2005;28(3):407-14. PMID 15868473
78: Nettesheim S, Kölker S, Karall D, et al. Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland. Orphanet J Rare Dis 2017;12(1):111. PMID 28619060
79: Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognized ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry 1998;64:680-2. PMID 9598692
80: Ohtani Y, Ohyanagi K, Yamamoto S, Matsuda I. Secondary carnitine deficiency in hyperammonemic attacks of ornithine transcarbamylase deficiency. J Pediatr 1988;112:409-14. PMID 3346778
81: Opladen T, Lindner M, Das AM, et al. In vivo monitoring of urea cycle activity with (13)C-acetate as a tracer of ureagenesis. Mol Genet Metab 2016;117(1):19-26. PMID 26597322
82: Ozturk K, McKinney AM, Nascene D. Urea cycle disorders: a neuroimaging pattern approach using diffusion and FLAIR MRI. J Neuroimaging 2021;31(1):144-50. PMID 32920938
83: Picca S, Dionisi-Vici C, Abeni D, et al. Extracorporal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol 2001;16(11):862-7. PMID 11685590
84: Plante RJ, Tuchman M. Polymorphisms in the human ornithine transcarbamylase gene useful for allele tracking. Mutation in brief no. 193. Online. Hum Mutat 1998;12:289-90. PMID 10660345
85: Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonemia. J Inherit Metab Dis 2000;23:129-36. PMID 10801054
86: Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis 2016;39(5):661-72. PMID 27106216
87: Posset R, Garbade SF, Boy N, et al. Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases. J Inherit Metab Dis 2019b;42(1):93-106. PMID 30740724
88: Posset R, Garbade SF, Gleich F, et al. Long-term effects of medical management on growth and weight in individuals with urea cycle disorders. Sci Rep 2020;10(1):11948. PMID 32686765
89: Posset R, Gropman AL, Nagamani SCS, et al. Impact of diagnosis and therapy on cognitive function in urea cycle disorders. Ann Neurol 2019a;86(1):116-28.** PMID 31018246
90: Ray PF, Gigarel N, Bonnefont JP, et al. First specific preimplantation genetic diagnosis for ornithine transcarbamylase deficiency. Prenat Diagn 2000;20:1048-54. PMID 11180228
91: Ricciuti F, Gelehrter TD, Rosenberg LE. X-chromosome inactivation in human liver: confirmation of X-linkage of ornithine transcarbamylase. Am J Hum Genet 1976;28:332-8. PMID 941900
92: Russell A, Levin B, Oberholzer VG, Sinclair L. Hyperammonaemia: a new instance of an inborn enzymatic defect of the biosynthesis of urea. Lancet 1962;2:699-700. PMID 13975632
93: Scaglia F, Zheng Q, O'Brien WE, et al. An integrated approach to the diagnosis and prospective management of partial ornithine transcarbamylase deficiency. Pediatrics 2002;109(1):150-2. PMID 11773558
94: Scharre S, Posset R, Garbade SF, et al. Predicting the disease severity in male individuals with ornithine transcarbamylase deficiency. Ann Clin Transl Neurol 2022;9(11):1715-26.** PMID 36217298
95: Seminara J, Tuchman M, Krivitzky L, et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab 2010;100 Suppl 1:S97-105. PMID 20188616
96: Sen K, Anderson AA, Whitehead MT, Gropman AL. Review of multi-modal imaging in urea cycle disorders: the old, the new, the borrowed, and the blue. Front Neurol 2021;12:632307. PMID 33995244
97: Schmidt J, Kroeber S, Irouschek A, Birkholz T, Schroth M, Albrecht S. Anesthetic management of patients with ornithine transcarbamylase deficiency. Paediatr Anaesth 2006;16(3):333-7. PMID 16490102
98: Shchelochkov OA, Li FY, Geraghty MT, et al. High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. Mol Genet Metab 2009;96(3):97-105. PMID 19138872
99: Short EM, Conn HO, Snodgrass PJ, et al. Evidence for X-linked dominant inheritance of ornithine transcarbamylase deficiency. N Engl J Med 1973;299:7-12. PMID 4681915
100: Soria LR, Brunetti-Pierri N. Ammonia and autophagy: an emerging relationship with implications for disorders with hyperammonemia. J Inherit Metab Dis 2019;42(6):1097-104. PMID 30671986
101: Staretz-Chacham O, Daas S, Ulanovsky I, et al. The role of orotic acid measurement in routine newborn screening for urea cycle disorders. J Inherit Metab Dis 2021;44(3):606-17. PMID 33190319
102: Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, mulitcentre study of acute hyperammonaemic episodes. Acta Paediatr 2008;97(10):1420-5.** PMID 18647279
103: Summar ML, Endo F, Kölker S. On the creation, utility and sustaining of rare diseases research networks: lessons learned from the Urea Cycle Disorders Consortium, the Japanese Urea Cycle Disorders Consortium and the European Registry and Network for Intoxication Type Metabolic Diseases. Mol Genet Metab 2014;113(1-2):105-8.** PMID 25261246
104: Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab 2013;110(1-2):179-80. PMID 23972786
105: Takanashi J, Barkovich AJ, Cheng SF, Kostiner D, Baker JC, Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. AJNR Am J Neuroradiol 2003;24(3):390-3. PMID 12637287
106: Teufel U, Weitz J, Flechtenmacher C, et al. High urgency liver transplantation in ornithine transcarbamylase deficiency presenting with acute liver failure. Pediatr Transplant 2011;15(6):E110-5. PMID 21884343
107: Toquet S, Spodenkiewicz M, Douillard C, et al. Adult-onset diagnosis of urea cycle disorders: results of a French cohort of 71 patients. J Inherit Metab Dis 2021;44(5):1199-214. PMID 34014557
108: Torkzaban M, Haddad A, Baxter JK, Berghella V, Gahl WA, Al-Kouatly HB. Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: a systematic review. Am J Med Genet A 2019;179(10):2091-100. PMID 31441224
109: Tuchman M. Persistent acitrullinemia following liver transplantation for carbamylphosphate synthetase deficiency. N Engl J Med 1989;320:1498-9. PMID 2654638
110: Tuchman M, Jaleel N, Morizono H, Sheehy L, Lynch MG. Mutations and polymorphisms in the human ornithine transcarbamylase gene. Hum Mutat 2002;19(2):93-107. PMID 11793468
111: Tuchman M, Matsuda I, Munnich A, et al. Proportions of spontaneous mutations in males and females with ornithine transcarbamylase deficiency. Am J Med Genet 1995;55:67-70. PMID 7702100
112: Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998;21:40-58. PMID 9686344
113: Tuchman M, Yudkoff M. Blood levels of ammonia and nitrogen scavenging amino acids in patients with inherited hyperammonemia. Mol Genet Metab 1999;66:10-5. PMID 9973542
114: Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. J Inherit Metab Dis 1998;21:151-9. PMID 9686352
115: van Karnebeek CD, Sly WS, Ross CJ, et al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. Am J Hum Gen 2014;94(3):453-61. PMID 24530203
116: Vasquez-Loarte T, Thompson JD, Lawrence Merritt 2nd J. Considering proximal urea cycle disorders in expanded newborn screening. Int J Neonatal Screen 2020;6(4):77. PMID 33124615
117: Waisbren SE, Gropman AL, Members of the Urea Cycle Disorders Consortium (UCDC), Batshaw ML. Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium. J Inherit Metab Dis 2016;39(4):573-84. PMID 27215558
118: Watanabe A, Sekizawa A, Taguchi A, et al. Prenatal diagnosis of ornithine transcarbamylase deficiency by using a single nucleated erythrocyte from maternal blood. Hum Genet 1998;102:611-5. PMID 9703419
119: Whittington PF, Alonso EM, Boyle JT, et al. Liver transplantation for the treatment of urea cycle disorders. J Inherit Metab Dis 1998;21:112-8. PMID 9686349
120: Yu L, Rayhill SC, Hsu EK, Landis CS. Liver transplantation for urea cycle disorders: analysis of the United Network for Organ Sharing Database. Transplant Proc 2015;47(8):2413-8. PMID 26518943
121: Zenker M, Wermuth B, Trautmann U, et al. Severe, neonatal-onset OTC deficiency in twin sisters with a de novo balanced reciprocal translocation t(X;5)(p21.1;q11). Am J Med Genet A. 2005;132:185-8. PMID 15578616
122: Zielonka M, Breuer M, Okun JG, Carl M, Hoffmann GF, Kolker S. Pharmacologic rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine aminotransferase. PLoS One 2018;13(9):e0203707. PMID 30199544
123: Zielonka M, Probst J, Carl M, Hoffmann GF, Kolker S, Okun JG. Bioenergetic dysfunction in a zebrafish model of acute hyperammonemic decompensation. Exp Neurol 2019;314:91-9. PMID 30653968
124: Ziogas IA, Kelly Wu W, Matsuoka LK, et al. Liver transplantation in children with urea cycle disorders: the importance of minimizing waiting time. Liver Transpl 2021. [Epub ahead of print] PMID 34058057
125: Zschocke J, Hoffmann GF. Vademecum metabolicum: manual of metabolic paediatrics. 3rd edition. Stuttgart: Schattauer Verlag, 2011.
126: Zschocke J, Hoffmann GF. Vademecum metabolicum: manual of metabolic paediatrics. 5th edition. Stuttgart: Thieme, 2020.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Roland Posset MD

Dr. Posset of the University Center for Child and Adolescent Medicine in Heidelberg received consultancy fees from Immedica Pharma AB.
See Profile
Matthias Zielonka MD

Dr. Zielonka of University Children’s Hospital Heidelberg has no relevant financial relationships to disclose.
See Profile
Georg F Hoffmann MD

Dr. Hoffmann of the University Center for Child and Adolescent Medicine in Heidelberg has no relevant financial relationships to disclose.
See Profile

Editor

Barry Wolf MD PhD

Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.
See Profile

Former Authors

Mendel Tuchman MD, Uta Lichter-Konecki MD PhD, and Mark L Batshaw MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: Female > male
Heredity: heredity may be a factor

heredity typical

X-linked partially dominant
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Disorders of urea cycle metabolism: 270.6
ICD-10: Disorders of urea cycle metabolism: E72.42
OMIM: Ornithine transcarbamylase deficiency: #311250

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Ornithine transcarbamylase deficiency

Associated Disorders

Ataxia
Cerebral palsy
Congenital hyperammonemia
Intellectual disability
Neuropsychiatric disease
- Seizure disorder
- Valproate toxicity
- Urea cycle disorders (others)
- Carbonic anhydrase VA deficiency
- Maple syrup urine disease
- N-acetylglutamate synthase deficiency
- Carbamoyl phosphate synthetase 1 deficiency
- Hyperinsulinism-hyperammonemia syndrome
- Carbonic anhydrase VA deficiency
- Reye syndrome

Differential Diagnosis

urea-cycle disorders (others)
amino acidopathies
congenital lactic acidoses
defects in fatty acid beta-oxidation
organic acidurias
- congenital lactic acidosis
- dibasic amino acid transport defects
- transient hyperammonemia of the newborn
- sepsis
- intracranial hemorrhage
- cardiorespiratory disorders
- valproate treatment
- hypoglycemia
- Reye syndrome
- hyperinsulinism-hyperammonemia syndrome
- liver disease
- drug toxicity
- hepatotoxins
- mitochondrial carbonic anhydrase VA deficiency

Also Relevant

Ataxia
Carbamoyl phosphate synthetase 1 deficiency
Citrullinemia
Hyperammonemia not caused by liver failure
Hyperargininemia
- Intellectual disability
- N-acetylglutamate synthase deficiency

Clinical Categories

Neurogenetic Disorders

Web References

Guidelines

NORD: Urea cycle disorders

Ornithine transcarbamylase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Management of acute hyperammonemia in OTCD.

Table 1. Protein, Liquid, and Glucose Management

Table 2. First-Line Medication for OTCD****

Long-term management of OTCD.

Table 3. Long-Term Medication for OTCD

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

POLG-related mitochondrial disorders

This is an article preview.
Start a Free Account
to access the full version.